Leadership - Eledon Pharmaceuticals, Inc.

David-Alexandre C. Gros, MD

Chief Executive Officer

Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

Steven Perrin, PhD

President and Chief Scientific Officer

Dr. Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc. before joining Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) He has 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the world’s largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.

Marina Escudero

Vice President, and Head of Clinical Operations

Ms. Escudero has served as Vice President, and Head of Clinical Operations since January 2024. Ms. Escudero has over 20 years of R&D experience in the pharmaceutical industry, where she has been involved in various stages of drug development, from early phase 1 trials to registrational phase 3 studies, which led to the successful registration of multiple small and large molecule pharmaceutical products. Prior to joining Eledon, Ms. Escudero served as VP of Clinical Development Operations at Leap Therapeutics, overseeing all operational facets of the clinical programs. Before Leap Therapeutics, she founded Caliber Clinical Consulting, LLC, providing independent consultation services to biopharmaceutical companies. Prior to Caliber Clinical Consulting, Ms. Escudero served as VP of Clinical Development Operations at Kiniksa Pharmaceuticals, where she managed multiple clinical programs at various stages of development. Ms. Escudero earned her B.S. in Behavior Neuroscience from Northeastern University.

John Herberger

Vice President, Technical Operations

Mr. Herberger has served as Vice President, Technical Operations of Eledon since May 2022. Prior to joining Eledon, Mr. Herberger served as Senior Director, Manufacturing Science & Technology of Spark Therapeutics. Prior to joining Sparks Therapeutics, he served 21 years at Amgen where he held numerous leadership roles in drug delivery & formulation, device development, technology transfer and global operations. Mr. Herberger previously served on the University of Rhode Island College of Environmental & Life Sciences Dean’s Advisory Council and Bio Science Leaders Forum. Prior to joining Amgen, Mr. Herberger was a Research Scientist at Alkermes Inc., where he contributed to the development of novel drug delivery systems and authored several publications and patents in the field. Mr. Herberger began his career as a founding member of the Institute of Molecular Biology. He holds a bachelor’s degree from the University of Albany, State University of New York.

David Hovland, PhD

Chief Regulatory Officer

Dr. Hovland has served as Chief Regulatory Officer of Eledon since April 2021. In this role, he is responsible for Eledon’s Regulatory, Quality, and Safety functions. He has over 20 years of R&D experience in the pharmaceutical industry, and has contributed to the global development and registration of multiple small and large molecule pharmaceutical products. Dr. Hovland joined Eledon from Urovant Sciences, where he served as Senior Vice President, Global Regulatory Affairs and Quality. Before Urovant Sciences, Dr. Hovland held leadership roles within the Global Regulatory Affairs organization at Allergan, most recently serving as the Regulatory Affairs Therapeutic Area Head for Neurology, Urology, and Dermatology, with a previous role as Head of the Global Regulatory Operations function. Before Allergan, Dr. Hovland worked in Amgen’s Global Regulatory Affairs and Safety organization, serving as a global regulatory strategy leader on pharmaceutical development teams. Dr. Hovland earned his Ph.D. in Environmental Health Sciences from the School of Public Health at the University of California, Los Angeles, and his B.S. in Bioresource Sciences from the College of Natural Resources at the University of California, Berkeley.

Eliezer Katz, MD, FACS

Chief Medical Officer

Dr. Katz has served as Chief Medical Officer of Eledon since November 2023. He joined Eledon Pharmaceuticals from eGenesis where he served as Chief Medical Officer. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA®(inebilizumab). Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. and Senior Director of Transplantation with the Medicine Development Group at Pfizer. Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem.

Paul Little

Chief Financial Officer

Mr. Little has served as Chief Financial Officer of Eledon since March 2021. Mr. Little has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., where he led finance, investor relations, information technology, and manufacturing. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) where he led the Company’s global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC’s Medical Aesthetics division and as a key member of the senior leadership team, helped build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.

Bryan Smith

General Counsel

Mr. Smith has served as General Counsel, Corporate Secretary, and Chief Compliance Officer of Eledon since April 2021. In this role, he is responsible for the Company’s legal, compliance, and corporate governance functions. Prior to joining Eledon, Mr. Smith served as General Counsel, Corporate Secretary, and Chief Compliance Officer of Urovant Sciences. Before Urovant Sciences, Mr. Smith held leadership roles at Allergan, most recently serving as Associate Vice President and chief counsel to the company’s urology, neurology, aesthetics, and dermatology business units. Prior to joining Allergan, Mr. Smith was a litigator at Gibson, Dunn & Crutcher LLP. Mr. Smith received his B.A. in Political Science from Brigham Young University and his J.D. from the University of Southern California Law School. After graduating from law school, Mr. Smith was a law clerk to the Honorable Cormac J. Carney in the United States District Court for the Central District of California.